Breaking News Instant updates and real-time market news.

VRX

Valeant

$12.92

-0.47 (-3.51%)

, RIG

Transocean

$11.05

0.19 (1.75%)

07:35
10/17/17
10/17
07:35
10/17/17
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Monday in Valeant (VRX), Transocean (RIG), T Mobile (TMUS), Himax (HIMX), Range Resources (RRC), Raytheon (RTN), Brookdale Senior Living (BKD), Olin Corp. (OLN), and Ultra Petroleum (UPL).

VRX

Valeant

$12.92

-0.47 (-3.51%)

RIG

Transocean

$11.05

0.19 (1.75%)

TMUS

T-Mobile

$60.97

-0.42 (-0.68%)

HIMX

Himax

$9.14

-0.19 (-2.04%)

RRC

Range Resources

$19.51

0.07 (0.36%)

RTN

Raytheon

$188.71

0.82 (0.44%)

BKD

Brookdale Senior Living

$10.12

0.02 (0.20%)

OLN

Olin

$35.46

-0.08 (-0.23%)

UPL

Ultra Petroleum

$8.15

0.04 (0.49%)

  • 25

    Oct

  • 01

    Nov

  • 02

    Nov

  • 07

    Nov

  • 07

    Nov

  • 15

    Nov

  • 16

    Nov

VRX Valeant
$12.92

-0.47 (-3.51%)

10/13/17
CANT
10/13/17
NO CHANGE
Target $23
CANT
Overweight
Concern over Valeant's financial controls 'likely just noise,' says Cantor
Cantor Fitzgerald analyst Louise Chen says she's received calls today regarding concerns about Valeant Pharmaceuticals' financial controls. As reported last night by The Fly, Wells Fargo analyst David Maris expressed concern over Valeant's controls after digging into the lawsuit from Depomed (DEPO). The shares in afternoon trading are down 4%, or 53c, to $13.32. Chen, after speaking with the company, believes the concerns are "likely just noise and cannot be strung together into an argument" that Valeant has issues with financial controls. She does not see any fundamental reasons for today's pullback. Valeant is already ahead of its debt pay-down objectives, and can lower its debt to four-to-five times EBITDA over the next several years, Chen tells investors in an afternoon research note titled "Tune Out The Noise, And Start The Weekend On A Positive Note." She keeps an Overweight rating on Valeant with a $23 price target.
10/12/17
WELS
10/12/17
NO CHANGE
Target $9
WELS
Underperform
Wells wonders about Valeant's financial controls amid Depomed lawsuit
On September 7, Depomed (DEPO) filed suit against Valeant Pharmaceuticals (VRX) for failure to pay royalties on Glumetza, Wells Fargo analyst David Maris tells investors in a research note titled "Another Dispute With Another Partner." Depomed claims more than $20M is owed and that its auditor KPMG uncovered that Valeant "failed to maintain full and accurate records of its Glumetza transactions," Maris points out. The analyst, who has a longstanding Underperform rating Valeant shares, says his interest in the case goes beyond the money owed and more to what it might suggest about the current state of the company's financial controls and the use of adjusted versus non-adjusted earnings. In addition to the Depomed lawsuit, Valeant is also in arbitration with Cosmo and Alfa Wasserman over Xifaxan and in litigation with former shareholders of Sprout regarding Addyi, Maris adds. He's interested in how Valeant intends to handle reporting for a potential settlement or payment related to the Depomed suit. Valeant closed today down 47c to $13.83, above Maris' price target of $9.00.
10/09/17
DBAB
10/09/17
NO CHANGE
Target $19
DBAB
Hold
Deutsche's gastroenterologist survey bodes well for Valeant
Deutsche Bank analyst Gregg Gilbert says his firm's survey of 25 primary care physicians that frequently prescribe drugs for irritable bowel syndrome bodes well for Valeant Pharmaceuticals (VRX) and less so for Allergan (AGN). The survey found doctors expect their prescribing for IBS with diarrhea to increase over the next year, Gilbert tells investors in a research note. They expect solid share growth for Valeant's Xifaxan and have more modest expectations for Allergan's Viberzi, Gilbert writes. The analyst has a Hold rating on Valeant and Buy rating on Allergan.
09/28/17
WELS
09/28/17
NO CHANGE
WELS
Underperform
Valeant attributes today's selloff to confusion about filing, says Wells Fargo
Valeant Pharmaceuticals suggested the 5% intraday pullback in its shares may be related to confusion about a recent regulatory filing concerning a potential offering, Wells Fargo analyst David Maris tells investors in a research note. The company's private placement exemption application relates to a potential placement of a maximum $1.5B in senior notes, not equity, Maris points out after speaking to Valeant. The company told Maris that some investors may have misread the filing as an exemption for a potential equity raise, which it is not. Valeant, though, previously said equity is not off the table as a means to bring down debt, which could have contributed to today's confusion, Maris writes in a late afternoon research note. He keeps an Underperform rating on Valeant shares, which are down in afternoon trading 4%, or 64c, to $13.75.
RIG Transocean
$11.05

0.19 (1.75%)

10/10/17
DBAB
10/10/17
INITIATION
Target $13
DBAB
Buy
Transocean initiated with a Buy at Deutsche Bank
Deutsche Bank analyst David Havens started Transocean with a Buy rating and $13 price target.
10/12/17
SBSH
10/12/17
UPGRADE
Target $14
SBSH
Buy
Transocean upgraded to Buy from Neutral at Citi
Citi analyst Scott Gruber upgraded Transocean (RIG) to Buy and raised his price target for the shares to $14 from $8.80. The analyst initiated a pair trade by also downgrading Diamond Offshore (DO) to Sell. Gruber, while still finding it premature to be bullish on offshore driller fundamentals, says that if an upturn is forthcoming, Transocean should outperform given a "diminution" of concern toward its balance sheet and more new contract catalysts. If the downturn persists, then Diamond Offshore is likely to underperform as its backlog is consumed, Gruber tells investors in a research note previewing Q3 earnings for the sector. He believes Diamond Offshore is "simply overvalued" and that Transocean is the "industry leader who's ready to lead."
10/12/17
SBSH
10/12/17
DOWNGRADE
Target $12
SBSH
Sell
Diamond Offshore downgraded to Sell from Neutral at Citi
Citi analyst Scott Gruber downgraded Diamond Offshore (DO) to Sell and keeps a $12 price target for the shares. The analyst initiated a pair trade by also upgrading Transocean (RIG) this morning to Buy. Gruber, while still finding it premature to be bullish on offshore driller fundamentals, says that if an upturn is forthcoming, Transocean should outperform given a "diminution" of concern toward its balance sheet and more new contract catalysts. If the downturn persists, then Diamond Offshore is likely to underperform as its backlog is consumed, Gruber tells investors in a research note previewing Q3 earnings for the sector. He believes Diamond Offshore is "simply overvalued" and that Transocean is the "industry leader who's ready to lead."
10/12/17
10/12/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Delta Air Lines (DAL) upgraded to Outperform from In-Line at Imperial Capital with analyst Michael Derchin saying the company is likely to grow unit revenues in fiscal year 2018 due to pricing power in its key domestic hubs and improving international results. 2. Transocean (RIG) upgraded to Buy from Neutral at Citi with analyst Scott Gruber saying if an upturn is forthcoming, Transocean should outperform given a "diminution" of concern toward its balance sheet and more new contract catalysts. 3. Canadian Pacific (CP) upgraded to Overweight from Neutral at JPMorgan with analyst Brian Ossenbeck saying he sees a shift to stronger volume growth as the company laps contract losses and records some new contract wins. 4. Infinity upgraded to Outperform from Market Perform at Wells Fargo with analyst Jim Birchenough saying the IPI-549 monotherapy data have a "reasonable likelihood" of proof-of-concept response rate, and with likely validation of tumor macrophage targeting in immunooncology and a unique mechanism of action, upside potential is not reflected in the current stock price. 5. Kroger (KR) upgraded to Equal Weight from Underweight at Stephens with analyst Ben Bienvenu saying he believes the pursuit of strategic alternatives for the convenience store business has potential to unlock value and that the risk/reward is more balanced following the stock's recent pullback. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TMUS T-Mobile
$60.97

-0.42 (-0.68%)

10/16/17
10/16/17
DOWNGRADE

Perform
Crown Castle downgraded to Perform at Oppenheimer
As previously reported, Oppenheimer analyst Timothy Horan downgraded Crown Castle (CCI) to Perform from Outperform saying that recent reports denote a T-Mobile (TMUS)/Sprint (S) merger is imminent, and as it represents 40% of revenues and will be aggressively slashing supplier spending, which will offset growth in 600 MHz, FirstNet, 5G. The analyst sees a 70% probability of the deal receiving approval with major concessions and likely also attacking the wireline market and better able to compete with Verizon (VZ)/AT&T (T) on coverage/capacity.
10/13/17
JPMS
10/13/17
NO CHANGE
Target $225
JPMS
Overweight
Netflix price target raised to $225 from $210 at JPMorgan
JPMorgan analyst Doug Anmuth raised his price target for Netflix (NFLX) shares to $225 ahead of the company's Q3 results on Monday, October 16. The analyst cites the recent price increase as well as the T-Mobile (TMUS) promotion for his higher target. He upped his estimate for Q3 U.S. net subscriber additions to 800,000 from 765,000 but lowered his Q4 estimate to 1.65M from 1.7M as he expects price increase-related churn to potentially offset the T-Mobile promotion. Netflix remains one of Anmuth's top two large-cap picks.
09/28/17
RAJA
09/28/17
NO CHANGE
RAJA
DOJ appointment catalyst for CenturyLink, Level 3 deal, says Raymond James
Makan Delrahim was finally confirmed by the Senate yesterday as head of the Department of Justice Antitrust Division, Raymond James analyst Frank Louthan tells investors in a research note. He believes not having an antitrust head is at least partially to blame for the delay in mergers and acquisitions in the Technology & Communications space this year, including outstanding transactions like CenturyLink (CTL)/Level 3 Communications (LVLT) and AT&T (T)/Time Warner (TWX), as well as potential deals like Sprint (S)/T-Mobile U.S. (TMUS). The appointment of Delrahim is a catalyst for the approval of CenturyLink's acquisition of Level 3, where the Department of Justice has been the bottleneck, Louthan writes.
09/27/17
KEYB
09/27/17
UPGRADE
Target $170
KEYB
Overweight
SBA Communications upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Brandon Nispel upgraded SBA Communications (SBAC) to Overweight saying fears surrounding carrier consolidation has created a buying opportunity. Even with potential churn from customer consolidation, SBA's organic growth should accelerate into 2018 and 2019 with "carrier LTE-Advanced investments paving the way for 5G," Nispel tells investors in a research note. He also believes e combined T-Mobile (TMUS) and Sprint (S) would require more sites, not fewer. The analyst established a $170 price target for shares of SBA Communications.
HIMX Himax
$9.14

-0.19 (-2.04%)

10/12/17
LSCM
10/12/17
NO CHANGE
Target $13
LSCM
Buy
Lake Street checks confirm Apple supply chain issues impacting Himax
Lake Street analyst Jaeson Schmidt says recent channel checks indicate the "well-rumored" supply chain issues at Apple (AAPL) and pushouts at Android manufacturers could create headwinds the rest of this year for Himax Technologies and cause 2018 to be more second half weighted than originally expected. The analyst, while admitting his upgrade of Himax two weeks ago was premature, keeps a Buy rating on the shares. Himax has not lost these sockets, but rather is being impacted by timetable shifts, Schmidt tells investors in a research note. He still believes the 3D sensing market has the potential to drive significant growth for the company longer-term. The analyst lowered his 2017 earnings per share estimate for Himax to 9c from 12c and 2018 estimate to 30c from 38c.
10/11/17
MZHO
10/11/17
DOWNGRADE
MZHO
Neutral
Himax downgraded to Neutral from Buy at Mizuho
Mizuho analyst Kevin Wang downgraded Himax to Neutral saying shares reflect the 3D sensing story in 2018-19.
09/28/17
LSCM
09/28/17
UPGRADE
Target $13
LSCM
Buy
Himax upgraded to Buy from Hold at Lake Street
Lake Street analyst Jaeson Schmidt upgraded Himax to Buy and increased its price target to $13 form $8.50 following recent management meetings. The analyst has increased confidence in growth opportunities and said the 3D sensing opportunity could be a "game-changer" for the company given the market size, ASP opportunity, and gross margin profiles.
09/15/17
09/15/17
UPGRADE
Target $62.5

Outperform
Qualcomm upgraded to Outperform on 3D sensing opportunity at Northland
As previously reported, Northland analyst Tom Sepenzis upgraded Qualcomm (QCOM) to Outperform from Market Perform on expectations for market share gains in 2018, particularly at the high end, as he sees the company and partner Himax (HIMX) as well positioned to become the "de facto leading 3D sensing solution" with Android manufacturers who follow the lead of Apple's (AAPL) new iPhone X. From what he understands, handset makers that want to use its SLiM structured light solution will have to use Qualcomm's next generation Snapdragon chipset too, he tells investors. Sepenzis keeps a $62.50 price target on Qualcomm shares.
RRC Range Resources
$19.51

0.07 (0.36%)

10/11/17
LEHM
10/11/17
UPGRADE
Target $24
LEHM
Overweight
Range Resources upgraded to Overweight from Underweight at Barclays
Barclays analyst Thomas Driscoll double upgraded Range Resources to Overweight from Underweight and raised his price target for the shares to $24 from $18. The shares are trading at their "most compelling level in years" are declining 50% over the 12 months, Driscoll tells investors in a research note. He expects Range's results will continue to improve in the Marcellus and believes its returns on new capital will meet or exceed peer averages.
09/08/17
GSCO
09/08/17
DOWNGRADE
Target $20.5
GSCO
Neutral
Range Resources downgraded to Neutral from Buy at Goldman Sachs
Goldman analyst Brian Singer downgraded Range Resources to Neutral and slashed its price target to $20.50 from $35 saying he sees less relative upside in a lower-for-longer gas price environment and notes the company less relative exposure to local Appalachian gas prices.
08/29/17
JEFF
08/29/17
NO CHANGE
Target $25
JEFF
Buy
Jefferies cuts oil forecast, Exploration & Production price targets
Jefferies lowered its Brent estimate to $57 per barrel from $64 in 2018, to $60 from $67 in 2019, and to $65 from $70 in 2020. The market appears to be adequately supplied in the near term, but depleting proved developed reserves and shrinking spare capacity should support rising longer-term price assumption, analyst Michael Hsu tells investors in a research note. To reflect the reduced forecast, the analyst cut his price targets for names in the Exploration & Production space. Target cuts include Buy-rated Carrizo Oil & Gas (CRZO) to $25 from $32, Buy-rated Continental Resources (CLR) to $42 from $52, Buy-rated Newfield Exploration (NFX) to $40 from $46, Buy-rated Noble Energy (NBL) to $32 from $36, Buy-rated Oasis Petroleum (OAS) to $13 from $16, Buy-rated Pioneer Natural Resources (PXD) to $171 from $192 and Buy-rated Range Resources (RRC) to $36 from $37.
09/20/17
WOLF
09/20/17
DOWNGRADE
WOLF
Underperform
Range Resources downgraded to Underperform from Peer Perform at Wolfe Research
Wolfe Research downgraded Range Resources to Underperform largely based on valuation and below average 2018 growth and margins versus peers.
RTN Raytheon
$188.71

0.82 (0.44%)

09/29/17
DBAB
09/29/17
UPGRADE
Target $210
DBAB
Buy
Deutsche sees rise in missile defense spending, upgrades Raytheon
Deutsche Bank analyst Myles Walton upgraded Raytheon (RTN) to Buy from Hold and raised his price target for the shares to $210 from $180. Raytheon is the most exposed to missile defense trends, Walton told investors earlier in a research note. He believes the politics and growing missile threats to U.S. territory are "setting the table for another leg up" in missile defense spending after declining nearly 25% over the last decade. The analyst sees his other Buy-rated defense names, including Northrop Grumman (NOC) and Lockheed Martin (LMT), benefiting as well. Walton raised his price target for Northrop to $325 from $285 and for Lockheed to $340 from $305.
09/29/17
09/29/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Southern Company (SO) upgraded to Outperform from Sector Perform at RBC Capital with analyst Shelby Tucker is increasingly convinced that the regulators are "committed to completing" the company's Vogtle project. 2. Conn's (CONN) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Nagel saying the company's credit business, under new CEO Norm Miller, is "on a much more solid footing, and supportive of a return to expansion in retail." 3. Raytheon (RTN) upgraded to Buy from Hold at Deutsche Bank with analyst Myles Walton saying Raytheon is the most exposed to missile defense trends. 4. USA Truck (USAK), J.B. Hunt (JBHT), and Heartland Express (HTLD) were upgraded to Buy from Hold at Stifel. 5. Zynerba (ZYNE) upgraded to Overweight from Neutral at Piper Jaffray analyst Charles Duncan saying without over-interpreting the results from this "modest open-label program," the data establish an "activity signal and tolerability profile that merits further placebo-controlled study." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/17
RBCM
10/09/17
NO CHANGE
Target $209
RBCM
Outperform
Defense and Aerospace sector poised for strong Q3, says RBC Capital
RBC Capital analyst Matthew McConnell previewed the Q3 earnings season for the defense and commercial aviation industries, raising price targets across the sectors. In defense, McConnell likes the companies with focus on international markets, where demand has not yet been reflected in orders or backlog. Among his favorites, McConnell raises the price target on Raytheon (RTN) to $209 from $193, General Dynamics (GD) to $241 from $220, Northrop Grumman (NOC) to $324 from $294, Lockheed Martin (LMT) to $327 from $289, and Triumph (TGI) to $38 from $33. He also states that there may be room for some consolidation in defense given that budget up-cycle is only 2 years old, profiling Astronics (ATRO), Barnes (B), Esterline (ESL), Heico (HEI), and Textron (TXT) as some of the potential targets. In commercial aviation, McConnell sees Boeing (BA) upside driven by continued strong air traffic growth, mature sales campaigns, and expectations for a strong wide-body replacement cycle starting in the early 2020s, raising his price target on Boeing to $269 from $235.
10/13/17
DBAB
10/13/17
NO CHANGE
DBAB
Deutsche Bank likes three Defense names into Q3 results
Ahead of the Aerospace & Defense earnings season which begins on October 18, Deutsche Bank analyst Myles Walton says he likes Boeing (BA), Huntington Ingalls (HII) and Raytheon (RTN) into the reports. Helping support the quarter was continued strong air traffic demand, inflecting defense spending outlays, and the increasing geopolitical threat environment, Walton tells investors in a research previewing the earnings for the sector. The analyst increased some price targets in the space, including Huntington Ingalls to $260 from $240, Barnes Group (B) to $77 from $70, Hexcel (HXL) to $66 from $60 and Spirit AeroSystems (SPR) to $83 from $75.
BKD Brookdale Senior Living
$10.12

0.02 (0.20%)

03/27/17
JEFF
03/27/17
UPGRADE
Target $16.5
JEFF
Buy
Brookdale Senior Living upgraded to Buy from Hold at Jefferies
Jefferies analyst Brian Tanquilut upgraded Brookdale Senior Living to Buy citing an improved risk/reward following the recent pullback in the shares. The analyst sees a greater than 50% probability that Brookdale's ongoing sale process results in a deal, but thinks the stock can reach $14.50 even without a takeout. He upped his price target for the shares to $16.50 from $14.
06/20/17
RBCM
06/20/17
NO CHANGE
RBCM
Deal suggests Brookdale Senior Living undervalued, says RBC Capital
RBC Capital analyst Frank Morgan estimates that Columbia Pacific Advisors paid about $2B, or $211,000-$249,000 per owned unit for Hawthorn Retirement Group. Applying the same valuation to Brookdale's owned units would imply a valuation of about $22 per share, the analyst stated. Adding in $5 per share would bring its total valuation to $27 per share, Morgan said. The stock closed at $14.78 yesterday.
07/26/17
STFL
07/26/17
NO CHANGE
STFL
CMS proposal negative for home health providers, says Stifel
Stifel analyst Chad Vanacore says that CMS proposed a 0.4% cut reduction in Medicare payments to home health agencies in 2018 and "potential deep cuts" in 2019. He views this development as negative for companies in the sector, "especially Kindred Healthcare (KND)." The analyst identifies Ensign Group (ENSG) and Brookdale Senior Living (BKD) as other affected companies in the sector. He keeps a Sell rating on Kindred, a Hold rating on Ensign ,and a Buy rating on Brookdale.
03/27/17
03/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Adobe (ADBE) upgraded to Buy from Neutral at BTIG. 2. Best Buy (BBY) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying store closures from hhgregg and potentially Sears (SHLD) could lift Best Buy's comp sales by 2%, Keith tells investors in a research note. Further, the upcoming iPhone and Samsung Galaxy Note launches should bring a "strong smartphone upgrade cycle," the analyst contends. 3. HCA Holdings (HCA) and Universal Health (UHS) were upgraded to Buy from Neutral at Mizuho. 4. Weatherford (WFT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Judson Bailey citing greater confidence in improving operations with the hire of CEO Mark McCollum and the formation of the OneStim joint venture. 5. Brookdale Senior Living (BKD) upgraded to Buy from Hold at Jefferies with analyst Brian Tanquilut citing an improved risk/reward following the recent pullback in the shares. The analyst sees a greater than 50% probability that Brookdale's ongoing sale process results in a deal, but thinks the stock can reach $14.50 even without a takeout. He upped his price target for the shares to $16.50 from $14. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
OLN Olin
$35.46

-0.08 (-0.23%)

10/10/17
COWN
10/10/17
NO CHANGE
Target $42
COWN
Outperform
Olin price target raised to $42 from $39 at Cowen
Cowen analyst Charles Nievert raised his price target on Olin to $42 from $39 to reflect his updated outlook on chlor-alkali and epoxy production and pricing, which he believes will be more robust than he initially estimated. Nievert reiterated his Outperform rating on Olin shares.
10/02/17
RHCO
10/02/17
NO CHANGE
RHCO
Olin price target raised to $44 from $36 at SunTrust
SunTrust analyst Jason Freuchtel raised his price target on Olin based on a $20 per ton increase in the price of caustic soda which was reportedly accepted by the market. The analyst increased his 2018 EBITDA estimate for the company to $1.29B. He expects the stock to command a higher multiple based on the increased outlook for caustic soda prices, and he keeps a Buy rating on the shares.
09/27/17
09/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX), JD.com (JD) initiated with an Outperform at Wells Fargo, and Baidu (BIDU) were initiated with an Outperform at Wells Fargo. 2. Zealand Pharma (ZEAL) initiated with a Buy at Goldman Sachs. 3. Olin (OLN) initiated with a Buy at Citi. 4. First Horizon (FHN) resumed with an Equal Weight at Morgan Stanley. 5. CRH (CRH) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/17
SBSH
09/27/17
INITIATION
Target $39
SBSH
Buy
Olin initiated with a Buy at Citi
Citi analyst Eric Petrie started Olin Corp. with a Buy rating and $39 price target. The analyst believes the electrochemical unit upcycle facilitated by industry rationalization and consolidation is in the early innings.
UPL Ultra Petroleum
$8.15

0.04 (0.49%)

06/12/17
STFL
06/12/17
UPGRADE
STFL
Buy
Ultra Petroleum upgraded on reorganization at Stifel
As noted earlier, Stifel upgraded Ultra Petroleum to Buy from Hold. Analyst Michael Scialla says that the company's reorganization has improved its balance sheet and margins, while leaving it "ready to compete." Target to $16 from $9.
06/12/17
06/12/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pandora (P) upgraded to Outperform from Market Perform at FBR Capital with analyst Barton Crockett saying he believes the setup for Pandora "looks enticing" given low investor expectations and the presence of John Malone following the investment by SiriusXM (SIRI). 2. Swift Transportation (SWFT) upgraded to Overweight from Equal Weight at Stephens. 3. Vodafone (VOD) upgraded to Buy from Hold at Argus with analyst John Eade saying he expects it profits to rise over the longer term. 4. Ultra Petroleum (UPL) upgraded to Buy from Hold at Stifel with analyst Michael Scialla saying the company's reorganization has improved its balance sheet and margins, while leaving it "ready to compete." 5. CACI (CACI) upgraded to Outperform from Market Perform at Cowen with analyst Cai von Rumohr citing its 2018 acceleration with strong bookings, the sector upturn, and a favorable risk/reward with support from its near peer-high cash flow yield. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/29/17
KLRG
08/29/17
INITIATION
Target $14
KLRG
Buy
Ultra Petroleum initiated with a Buy at KLR Group
KLR Group analyst John Gerdes started Ultra Petroleum with a Buy rating and $14 price target.
06/12/17
STFL
06/12/17
UPGRADE
STFL
Buy
Ultra Petroleum upgraded to Buy from Hold at Stifel

TODAY'S FREE FLY STORIES

TSLA

Tesla

$315.05

2.55 (0.82%)

10:21
11/18/17
11/18
10:21
11/18/17
10:21
Periodicals
Tesla new super car to cost $200,000, Recode says »

Alongside its new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 16

    Jan

GT

Goodyear Tire

$29.94

0.63 (2.15%)

10:17
11/18/17
11/18
10:17
11/18/17
10:17
Hot Stocks
Goodyear Tire, NASCAR extend relationship »

NASCAR and Goodyear Tire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Jan

  • 16

    Jan

HMC

Honda

$32.62

0.02 (0.06%)

10:05
11/18/17
11/18
10:05
11/18/17
10:05
Periodicals
Honda recalls 900,000 minivans on tip forward seats, Reuters says »

Honda Motor is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.43

-0.82 (-0.92%)

09:48
11/18/17
11/18
09:48
11/18/17
09:48
Periodicals
Activist investors Nelson Peltz still in P&G picture, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

, GE

General Electric

$18.21

-0.04 (-0.22%)

09:39
11/18/17
11/18
09:39
11/18/17
09:39
Periodicals
Buy Baker Hughes, Barron's says »

While it is "not…

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

GE

General Electric

$18.21

-0.04 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

CSCO

Cisco

$35.90

0.02 (0.06%)

09:19
11/18/17
11/18
09:19
11/18/17
09:19
Periodicals
More needed for Cisco to have 'groove back,' Barron's says »

While the Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

IBM

IBM

$148.97

-0.15 (-0.10%)

09:10
11/18/17
11/18
09:10
11/18/17
09:10
Periodicals
IBM could be next to fetch higher valuation, Barron's says »

Investors are warming to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

GE

General Electric

$18.21

-0.04 (-0.22%)

09:05
11/18/17
11/18
09:05
11/18/17
09:05
Periodicals
Option play offer some help given GE dividend, depressed stock, Barron's says »

While wagering against…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

09:00
11/18/17
11/18
09:00
11/18/17
09:00
Periodicals
Risk remains after GE dividend cut, Barron's says »

While buying General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$88.72

0.71 (0.81%)

, T

AT&T

$34.51

-0.01 (-0.03%)

08:21
11/18/17
11/18
08:21
11/18/17
08:21
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWX

Time Warner

$88.72

0.71 (0.81%)

T

AT&T

$34.51

-0.01 (-0.03%)

NYT

New York Times

$17.65

0.05 (0.28%)

TEX

Terex

$44.82

0.8 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

TPIC

TPI Composites

$19.06

-0.97 (-4.84%)

07:25
11/18/17
11/18
07:25
11/18/17
07:25
Conference/Events
TPI Composites to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SYNA

Synaptics

$38.21

0.57 (1.51%)

04:55
11/18/17
11/18
04:55
11/18/17
04:55
Conference/Events
Synaptics management to meet with KeyBanc »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$238.02

-1.35 (-0.56%)

17:23
11/17/17
11/17
17:23
11/17/17
17:23
Periodicals
Goldman Sachs has $510M lawsuit dismissed, Reuters reports »

A $510M lawsuit that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.94

-0.02 (-1.02%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Breaking Hot Stocks news story on Vical »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Ligand director sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CFO sells 6,559 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CEO sells 5,269 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$9.01

0.13 (1.46%)

17:15
11/17/17
11/17
17:15
11/17/17
17:15
Hot Stocks
Breaking Hot Stocks news story on MBIA »

Fine Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBCN

Rubicon

$8.07

0.1218 (1.53%)

17:03
11/17/17
11/17
17:03
11/17/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Rubicon »

Bandera Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.